The Ataxia Charlevoix-Saguenay Foundation is pleased to announce the newest member of its Board of Directors. As vice-president at Neuron23, Dr. Luc Desnoyers is leading the biomarker and diagnostics efforts to move programs from the late-stage research to clinical proof of concept. He has a vast experience in the biopharmaceutical industry.

“Dr. Desnoyers, with his specific areas of expertise, will contribute to our strategic directions and be instrumental in helping us prepare for clinical trials”  mentioned Jean Groleau, president of the Foundation.